Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

Authors

Neeltje Steeghs, Netherlands Cancer Institute
Haeseong Park, Washington University School of Medicine in St. Louis
et al.

Journal

Clinical and Translational Science

Publication Date

11-1-2022

Volume

15

Issue

11

First Page

2625

Last Page

2639

Document Type

Open Access Publication

DOI

10.1111/cts.13387

Rights and Permissions

Steeghs, N, Hansen, AR, Hanna, GJ, et al. Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development. Clin Transl Sci. 2022; 15: 2625- 2639. doi:10.1111/cts.13387 © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Recommended Citation

Steeghs, Neeltje; Park, Haeseong; and et al., "Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development." Clinical and Translational Science. 15, 11. 2625 - 2639. (2022).
https://digitalcommons.wustl.edu/oa_4/1739

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.